Publication:
Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

dc.contributor.authorCortegiani, Andrea
dc.contributor.authorMadotto, Fabiana
dc.contributor.authorGregoretti, Cesare
dc.contributor.authorBellani, Giacomo
dc.contributor.authorLaffey, John G
dc.contributor.authorPham, Tai
dc.contributor.authorVan Haren, Frank
dc.contributor.authorGiarratano, Antonino
dc.contributor.authorAntonelli, Massimo
dc.contributor.authorPesenti, Antonio
dc.contributor.authorGrasselli, Giacomo
dc.contributor.authorLUNG SAFE Investigators ESICM T
dc.date.accessioned2024-09-06T09:53:47Z
dc.date.available2024-09-06T09:53:47Z
dc.date.issued2018-06-12
dc.description.abstractBackground: The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life- sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge.en
dc.description.sponsorshipThe authors received no funding for this study. However, the LUNG SAFE study was funded and supported by the European Society of Intensive Care Medicine (ESICM; Brussels, Belgium), St. Michael's Hospital (Toronto, ON, Canada), and the University of Milano-Bicocca (Monza, Italy).es_ES
dc.format.page157es_ES
dc.format.volume22es_ES
dc.identifier.citationCortegiani A, Madotto F, Gregoretti C, Bellani G, Laffey JG, Pham T, et al. Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database. Crit Care. 2018 Jun 12;22:157.en
dc.identifier.doi10.1186/s13054-018-2079-9
dc.identifier.e-issn1364-8535es_ES
dc.identifier.issn1466-609X
dc.identifier.journalCritical Carees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/9251
dc.identifier.pubmedID29895331es_ES
dc.identifier.puiL622519494
dc.identifier.scopus2-s2.0-85048497595
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22541
dc.identifier.wos435422000002
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://dx.doi.org/10.1186/s13054-018-2079-9en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAcute respiratory failure
dc.subjectARDS
dc.subjectImmunocompromised patients
dc.subjectMechanical ventilation
dc.subjectNoninvasive ventilation
dc.subject.decsEstudios de Cohortes*
dc.subject.decsResultado del Tratamiento*
dc.subject.decsModelos Logísticos*
dc.subject.decsHuésped Inmunocomprometido*
dc.subject.decsBases de Datos Factuales*
dc.subject.decsFemenino*
dc.subject.decsEstadísticas no Paramétricas*
dc.subject.decsUnidades de Cuidados Intensivos*
dc.subject.decsMasculino*
dc.subject.decsFactores de Riesgo*
dc.subject.decsHumanos*
dc.subject.decsPersona de Mediana Edad*
dc.subject.decsEstudios Prospectivos*
dc.subject.decsEstimación de Kaplan-Meier*
dc.subject.decsAnciano*
dc.subject.decsÍndice de Severidad de la Enfermedad*
dc.subject.decsAnciano de 80 o más Años*
dc.subject.decsAdulto*
dc.subject.decsRespiración Artificial*
dc.titleImmunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE databaseen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files